This bilateral collaboration project relies on the joint venture’s production infrastructure and its access to raw material markets, optimizing resources to ensure the sustainable supply of this essential medication for Cuban patients, BioCubaFarma published on its Facebook profile.
Under this business modality, the demand for 81-milligram aspirin from the Cuban Public Health Ministry (MINSAP) to the industry is expected by 2026.
The Hubei C&C company, located in the Chinese city of Wuhan, will produce this high-demand medicine based on the transfer of technology from Cuba’s Medsol Laboratories.
jdt/iff/mem/dla
